<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="191">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05158660</url>
  </required_header>
  <id_info>
    <org_study_id>intracerebral hematoma</org_study_id>
    <nct_id>NCT05158660</nct_id>
  </id_info>
  <brief_title>Assessment of Intracerebral Hematoma</brief_title>
  <official_title>Assessment of Intracerebral Hematoma Using Transcranial Duplex _ Hospital Based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess acute intracerebral hematoma expansion within the first 48 hours from&#xD;
      the onset using transcranial duplex sonography in patients who have acute intracerebral&#xD;
      hematoma , and will also assess the correlation between the transcranial duplex sonography&#xD;
      measurements and the clinical outcome of these patients .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in volume of intracerebral hematoma</measure>
    <time_frame>at baseline, then 24 hour after the baseline, and finally 48 hours after the baseline</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Intracerebral Hematoma</condition>
  <arm_group>
    <arm_group_label>patients assessed by transcranial duplex sonography</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial duplex sonography</intervention_name>
    <description>it is an imaging device that will measure the intracerebral hematoma expansion</description>
    <arm_group_label>patients assessed by transcranial duplex sonography</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. first ever non traumatic supratentorial primary intracerebral haemorrhage on non&#xD;
             contrast CT brain&#xD;
&#xD;
          2. admitted within 24 hours of symptom onset&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. blood diseases, decompansated hepatic or renal impairment, or encephalopathy caused by&#xD;
             electrolyte disturbance&#xD;
&#xD;
          2. on anticoagulant treatment&#xD;
&#xD;
          3. if devolped major complications during hospitalization ( e.g sever chest infection,&#xD;
             hypoxia, or deep venous thrombosis )&#xD;
&#xD;
          4. comorbid neurological or psychiatric disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>waleed Gafar</last_name>
    <phone>00201012110708</phone>
    <email>waleed.gafar1995@gmail.com</email>
  </overall_contact>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 3, 2021</study_first_submitted>
  <study_first_submitted_qc>December 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Waleed Mohammed Gafar</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

